Skip to main content

Advertisement

SpringerLink
Log in

Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases

  • PERSPECTIVE
  • Published:
Journal of Neuroimmune Pharmacology Aims and scope Submit manuscript

Abstract

Platelet-derived growth factor (PDGF) is a family of mesenchymal mitogens with important functions during the embryonal development and in the control of tissue homeostasis in the adult. The PDGF isoforms exert their effects by binding to α–and β-tyrosine kinase receptors. Overactivity of PDGF signaling has been linked to the development of certain malignant and non-malignant diseases, including atherosclerosis and various fibrotic diseases. Different types of PDGF antagonists have been developed, including inhibitory monoclonal antibodies and DNA aptamers against PDGF isoforms and receptors, and receptor tyrosine kinase inhibitors. Beneficial effects have been recorded using such inhibitors in preclinical models and in patients with certain malignant as well as non-malignant diseases. The present communication summarizes the use of PDGF antagonists in the treatment of non-malignant diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201(6):925–935

    CAS  PubMed Central  PubMed  Google Scholar 

  • Abrams MB, Nilsson I, Lewandowski SA, Kjell J, Codeluppi S, Olson L, Eriksson U (2012) Imatinib enhances functional outcome after spinal cord injury. PLoS One 7(6):e38760

    CAS  PubMed Central  PubMed  Google Scholar 

  • Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, Zwerina J, Gay S, Schett G, Distler O et al (2008) Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 22(7):2214–2222

    CAS  PubMed  Google Scholar 

  • Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH (2009) Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 60(1):219–224

    CAS  PubMed  Google Scholar 

  • Aman J, van Bezu J, Damanafshan A, Huveneers S, Eringa EC, Vogel SM, Groeneveld AB, Vonk Noordegraaf A, van Hinsbergh VW, van Nieuw Amerongen GP (2012) Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation 126(23):2728–2738

    CAS  PubMed  Google Scholar 

  • Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276–1312

    CAS  PubMed Central  PubMed  Google Scholar 

  • Antoniu SA (2012) Targeting PDGF pathway in pulmonary arterial hypertension. Expert Opin Ther Targets 16(11):1055–1063

    CAS  PubMed  Google Scholar 

  • Arcot SS, Lipke DW, Gillespie MN, Olson JW (1993) Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 46(6):1086–1091

    CAS  PubMed  Google Scholar 

  • Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K et al (2010) Pericytes regulate the blood–brain barrier. Nature 468(7323):557–561

    CAS  PubMed  Google Scholar 

  • Balada E, Simeon-Aznar CP, Ordi-Ros J, Rosa-Leyva M, Selva-O’Callaghan A, Pardos-Gea J, Fonollosa-Pla V, Vilardell-Tarres M (2008) Anti-PDGFR-α antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann Rheum Dis 67(7):1027–1029

    CAS  PubMed  Google Scholar 

  • Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, Kinsella JP, Abman SH (2003) Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284(5):L826–L833

    CAS  PubMed  Google Scholar 

  • Banai S, Wolf Y, Golomb G, Pearle A, Waltenberger J, Fishbein I, Schneider A, Gazit A, Perez L, Huber R et al (1998) PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 97(19):1960–1969

    CAS  PubMed  Google Scholar 

  • Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas OA, Linkesch W (2002) Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99(1):381–383

    CAS  PubMed  Google Scholar 

  • Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15(4):255–273

    CAS  PubMed  Google Scholar 

  • Boor P, Konieczny A, Villa L, Kunter U, van Roeyen CR, LaRochelle WJ, Smithson G, Arrol S, Ostendorf T, Floege J (2007) PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant 22(5):1323–1331

    CAS  PubMed  Google Scholar 

  • Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R (2007) Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 46(6):1064–1074

    CAS  PubMed  Google Scholar 

  • Boström H, Willetts K, Pekny M, Levéen P, Lindahl P, Hedstrand H, Pekna M, Hellström M, Gebre-Medhin S, Schalling M et al (1996) PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85(6):863–873

    PubMed  Google Scholar 

  • Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J (2003) LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300(5617):329–332

    CAS  PubMed  Google Scholar 

  • Bueso-Ramos CE, Cortes J, Talpaz M, O’Brien S, Giles F, Rios MB, Medeiros LJ, Kantarjian H (2004) Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 101(2):332–336

    CAS  PubMed  Google Scholar 

  • Cai Y, Han M, Luo L, Song W, Zhou X (1996) Increased expression of PDGF and c-myc genes in lungs and pulmonary arteries of pulmonary hypertensive rats induced by hypoxia. Chin Med Sci J 11(3):152–156

    CAS  PubMed  Google Scholar 

  • Calver AR, Hall AC, Yu WP, Walsh FS, Heath JK, Betsholtz C, Richardson WD (1998) Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron 20(5):869–882

    CAS  PubMed  Google Scholar 

  • Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS et al (2005) Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 102(9):3389–3394

    CAS  PubMed Central  PubMed  Google Scholar 

  • Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA (2009) Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 53(1):129–132

    PubMed  Google Scholar 

  • Chen H, Gu X, Liu Y, Wang J, Wirt SE, Bottino R, Schorle H, Sage J, Kim SK (2011a) PDGF signalling controls age-dependent proliferation in pancreatic β-cells. Nature 478(7369):349–355

    CAS  PubMed Central  PubMed  Google Scholar 

  • Chen YT, Chang FC, Wu CF, Chou YH, Hsu HL, Chiang WC, Shen J, Chen YM, Wu KD, Tsai TJ et al (2011b) Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 80(11):1170–1181

    CAS  PubMed  Google Scholar 

  • Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL et al (2009) Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 60(2):584–591

    CAS  PubMed Central  PubMed  Google Scholar 

  • Classen J-F, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikström G, Rorsman C, Lenglez S, Franck-Larsson K, Tomasi J-P et al (2009) Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 60(4):1137–1144

    CAS  PubMed  Google Scholar 

  • Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, Schirmacher P, Biesterfeld S, Galle PR, Lohse AW et al (2006) Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 45(3):419–428

    CAS  PubMed  Google Scholar 

  • Dahal BK, Heuchel R, Pullamsetti SS, Wilhelm J, Ghofrani HA, Weissmann N, Seeger W, Grimminger F, Schermuly RT (2011) Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β. Pulm Circ 1(2):259–268

    CAS  PubMed Central  PubMed  Google Scholar 

  • Dai Y (2010) Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature. Expert Opin Ther Pat 20(7):885–897

    CAS  PubMed  Google Scholar 

  • Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR (2010) Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 181(6):604–610

    CAS  PubMed  Google Scholar 

  • Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7):2640–2653

    CAS  PubMed  Google Scholar 

  • Demetri GD (2011) Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 38(Suppl 1):S10–S19

    CAS  PubMed  Google Scholar 

  • Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA (2003) Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9(10):1306–1312

    PubMed  Google Scholar 

  • Ding H, Wu X, Bostrom H, Kim I, Wong N, Tsoi B, O’Rourke M, Koh GY, Soriano P, Betsholtz C et al (2004) A specific requirement for PDGF-C in palate formation and PDGFR-α signaling. Nat Genet 36(10):1111–1116

    CAS  PubMed  Google Scholar 

  • Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S et al (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56(1):311–322

    CAS  PubMed  Google Scholar 

  • Distler JH, Manger B, Spriewald BM, Schett G, Distler O (2008) Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 58(8):2538–2542

    CAS  PubMed  Google Scholar 

  • Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037

    CAS  PubMed  Google Scholar 

  • Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S (2011) Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 38(1):218–220

    CAS  PubMed  Google Scholar 

  • Egawa-Tsuzuki T, Ohno M, Tanaka N, Takeuchi Y, Uramoto H, Faigle R, Funa K, Ishii Y, Sasahara M (2004) The PDGF B-chain is involved in the ontogenic susceptibility of the developing rat brain to NMDA toxicity. Exp Neurol 186(1):89–98

    CAS  PubMed  Google Scholar 

  • Eitner F, Bucher E, van Roeyen C, Kunter U, Rong S, Seikrit C, Villa L, Boor P, Fredriksson L, Backstrom G et al (2008) PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 19(2):281–289

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R (1991) Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253:1129–1132

    CAS  PubMed  Google Scholar 

  • Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, Gill SC, Green LS, Janjic N (1999) Novel approach to specific growth factor inhibition in vivo. Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 154(1):169–179

    CAS  PubMed Central  PubMed  Google Scholar 

  • Floege J, Eitner F, Alpers CE (2008) A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 19(1):12–23

    CAS  PubMed  Google Scholar 

  • Fredriksson L, Li H, Fieber C, Li X, Eriksson U (2004) Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 23(19):3793–3802

    CAS  PubMed Central  PubMed  Google Scholar 

  • Fredriksson L, Nilsson I, Su EJ, Andrae J, Ding H, Betsholtz C, Eriksson U, Lawrence DA (2012) Platelet-derived growth factor C deficiency in C57BL/6 mice leads to abnormal cerebral vascularization, loss of neuroependymal integrity, and ventricular abnormalities. Am J Pathol 180(3):1136–1144

    CAS  PubMed Central  PubMed  Google Scholar 

  • Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134(6):1655–1669

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gay S, Jones REJ, Huang GQ, Gay RE (1989) Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 92:301–303

    CAS  PubMed  Google Scholar 

  • Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D et al (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161(6):1163–1177

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F et al (2010) Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182(9):1171–1177

    CAS  PubMed Central  PubMed  Google Scholar 

  • Giese NA, Marijianowski MMH, McCook O, Hancock A, Ramakrishnan V, Fretto LJ, Chen C, Kelly AB, Koziol JA, Wilcox JN et al (1999) The role of α and β platelet-derived growth factor receptor in the vascular response to injury in nonhuman primates. Arterioscler Thromb Vasc Biol 19(4):900–909

    CAS  PubMed  Google Scholar 

  • Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ (2001) PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59(4):1324–1332

    CAS  PubMed  Google Scholar 

  • Gordon JK, Spiera RF (2010) Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Curr Opin Rheumatol 22(6):690–695

    CAS  PubMed  Google Scholar 

  • Green LS, Jellinek D, Jenison R, Östman A, Heldin C-H, Janjic N (1996) Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35(45):14413–14424

    CAS  PubMed  Google Scholar 

  • Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685–1695

    CAS  PubMed  Google Scholar 

  • Hart CE, Kraiss LW, Vergel S, Gilbertson D, Kenagy R, Kirkman T, Crandall DL, Tickle S, Finney H, Yarranton G et al (1999) PDGFβ receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 99(4):564–569

    CAS  PubMed  Google Scholar 

  • Hawthorne T, Giot L, Blake L, Kuang B, Gerwien R, Smithson G, Hahne W, Mansfield T, Starling GC, Pochart P et al (2008) A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther 46(5):236–244

    CAS  PubMed  Google Scholar 

  • Heldin C-H, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283–1316

    CAS  PubMed  Google Scholar 

  • Heldin C-H, Rubin K, Pietras K, Östman A (2004) High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4(10):806–813

    CAS  PubMed  Google Scholar 

  • Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T (2009) Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 157(2):258–270

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, Brummendorf TH, Klose H (2011) Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 11:30

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hoch RV, Soriano P (2003) Roles of PDGF in animal development. Development 130(20):4769–4784

    CAS  PubMed  Google Scholar 

  • Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, Gomez-Sanchez MA, Grimminger F, Grunig E, Hassoun PM et al (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation 127(10):1128–1138

    CAS  PubMed  Google Scholar 

  • Huang Q, Sun R (1997) Changes of PDGF-α and β receptor gene expression in hypoxic rat pulmonary vessels. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 19(6):470–473

    CAS  PubMed  Google Scholar 

  • Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, Capron F, Galanaud P, Duroux P, Simonneau G et al (1998) Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11(3):554–559

    CAS  PubMed  Google Scholar 

  • Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS (2010) Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176(1):85–97

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hunzelmann N, Brinckmann J (2010) What are the new milestones in the pathogenesis of systemic sclerosis? Ann Rheum Dis 69(Suppl 1):i52–i56

    CAS  PubMed  Google Scholar 

  • Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23(5):973–981

    CAS  PubMed  Google Scholar 

  • Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG (2011) Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 117(4):c312–c319

    CAS  PubMed  Google Scholar 

  • Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R (1992) Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175(5):1413–1416

    CAS  PubMed  Google Scholar 

  • Karlsson L, Lindahl P, Heath JK, Betsholtz C (2000) Abnormal gastrointestinal development in PDGF-A and PDGFR-α deficient mice implicates a novel mesenchymal structure with putative instructive properties in villus morphogenesis. Development 127(16):3457–3466

    CAS  PubMed  Google Scholar 

  • Katayose D, Ohe M, Yamauchi K, Ogata M, Shirato K, Fujita H, Shibahara S, Takishima T (1993) Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension. Am J Physiol 264(2 Pt 1):L100–L106

    CAS  PubMed  Google Scholar 

  • Kavian N, Servettaz A, Marut W, Nicco C, Chereau C, Weill B, Batteux F (2012) Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor beta in the skin of mice with scleroderma-like features and prevents the development of the disease. Arthritis Rheum 64(6):1990–2000

    CAS  PubMed  Google Scholar 

  • Keramati AR, Singh R, Lin A, Faramarzi S, Ye ZJ, Mane S, Tellides G, Lifton RP, Mani A (2011) Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 108(5):1914–1918

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908–916

    PubMed  Google Scholar 

  • Kono SA, Heasley LE, Doebele RC, Camidge DR (2012) Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets 12(2):107–123

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kurasawa K, Arai S, Owada T, Maezawa R, Kumano K, Fukuda T (2010) Autoantibodies against platelet-derived growth factor receptor α in patients with systemic lupus erythematosus. Mod Rheumatol 20(5):458–465

    CAS  PubMed  Google Scholar 

  • Lanner MC, Raper M, Pratt WM, Rhoades RA (2005) Heterotrimeric G proteins and the platelet-derived growth factor receptor-β contribute to hypoxic proliferation of smooth muscle cells. Am J Respir Cell Mol Biol 33(4):412–419

    CAS  PubMed  Google Scholar 

  • Lazar J, Poonawalla T, Teng JM (2011) A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy. Pediatr Dermatol 28(2):172–175

    PubMed  Google Scholar 

  • Lei H, Rheaume MA, Kazlauskas A (2010) Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res 90(3):376–381

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lei H, Velez G, Kazlauskas A (2011) Pathological signaling via platelet-derived growth factor receptor α involves chronic activation of Akt and suppression of p53. Mol Cell Biol 31(9):1788–1799

    CAS  PubMed Central  PubMed  Google Scholar 

  • Leppänen O, Miyazawa K, Bäckström G, Pietras K, Sjöblom T, Heldin C-H, Östman A (2000) Predimerization of recombinant platelet-derived growth factor receptor extracellular domains increases antagonistic potency. Biochemistry 39(9):2370–2375

    PubMed  Google Scholar 

  • Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C (1994) Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8(16):1875–1887

    PubMed  Google Scholar 

  • Lewis CD, Olson NE, Raines EW, Reidy MA, Jackson CL (2001) Modulation of smooth muscle proliferation in rat carotid artery by platelet-derived mediators and fibroblast growth factor-2. Platelets 12(6):352–358

    CAS  PubMed  Google Scholar 

  • Li M, Abdollahi A, Grone HJ, Lipson KE, Belka C, Huber PE (2009) Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat Oncol 4:66

    PubMed Central  PubMed  Google Scholar 

  • Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R (2011) Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 10(10):590–594

    CAS  PubMed  Google Scholar 

  • Liao CH, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y, Yamamoto R, Ozasa Y, Fujimoto M, Wang P et al (2010) Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 120(1):242–253

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lin SL, Kisseleva T, Brenner DA, Duffield JS (2008) Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173(6):1617–1627

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lindahl P, Johansson BR, Levéen P, Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277(5323):242–245

    CAS  PubMed  Google Scholar 

  • Liu Y, Wang Z, Kwong SQ, Lui EL, Friedman SL, Li FR, Lam RW, Zhang GC, Zhang H, Ye T (2011) Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 55(3):612–625

    CAS  PubMed  Google Scholar 

  • Llanos L, Bellot P, Zapater P, Perez-Mateo M, Such J (2009) Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib. Am J Gastroenterol 104(1):257–258

    PubMed  Google Scholar 

  • Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L, Wigley F, Kussie P (2009) Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 60(4):1145–1151

    CAS  PubMed  Google Scholar 

  • Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM et al (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47(27):6658–6661

    CAS  PubMed  Google Scholar 

  • Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, Leroy EC, Sutherland S, Silver RM (1995) Elevated levels of platelet derived growth factor and transforming growth factor-β1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22(10):1876–1883

    CAS  PubMed  Google Scholar 

  • Ma Q, Huang B, Khatibi N, Rolland W 2nd, Suzuki H, Zhang JH, Tang J (2011) PDGFR-α inhibition preserves blood–brain barrier after intracerebral hemorrhage. Ann Neurol 70(6):920–931

    CAS  PubMed Central  PubMed  Google Scholar 

  • Maeda Y, Hirano K, Hirano M, Kikkawa Y, Kameda K, Sasaki T, Kanaide H (2009) Enhanced contractile response of the basilar artery to platelet-derived growth factor in subarachnoid hemorrhage. Stroke 40(2):591–596

    PubMed  Google Scholar 

  • Mani A, Radhakrishnan J, Wang H, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315(5816):1278–1282

    CAS  PubMed Central  PubMed  Google Scholar 

  • Martin IV, Borkham-Kamphorst E, Zok S, van Roeyen CR, Eriksson U, Boor P, Hittatiya K, Fischer HP, Wasmuth HE, Weiskirchen R et al (2013) Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. Am J Pathol 182(1):107–117

    CAS  PubMed  Google Scholar 

  • Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A (2009) Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 43(12):967–968

    CAS  PubMed  Google Scholar 

  • Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, Michel BA, Gay S, Distler JH, Distler O (2012) Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 71(8):1382–1387

    CAS  PubMed  Google Scholar 

  • Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49(4):1245–1256

    CAS  PubMed  Google Scholar 

  • Nguyen PT, Nakamura T, Hori E, Urakawa S, Uwano T, Zhao J, Li R, Bac ND, Hamashima T, Ishii Y et al (2011) Cognitive and socio-emotional deficits in platelet-derived growth factor receptor-β gene knockout mice. PLoS One 6(3):e18004

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ogawa S, Ochi T, Shimada H, Inagaki K, Fujita I, Nii A, Moffat MA, Katragadda M, Violand BN, Arch RH et al (2010) Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol Res 40(11):1128–1141

    CAS  PubMed  Google Scholar 

  • Olson LE, Soriano P (2011) PDGFRβ signaling regulates mural cell plasticity and inhibits fat development. Dev Cell 20(6):815–826

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ostendorf T, Eitner F, Floege J (2012) The PDGF family in renal fibrosis. Pediatr Nephrol 27(7):1041–1050

    PubMed  Google Scholar 

  • Östman A, Heldin C-H (2013) Platelet-derived growth factor. In: Gelmann E, Sawers C, Rauscher F III (eds) Molecular oncology: Causes of cancer and targets for treatment. Cambridge University Press, Cambridge, in press

    Google Scholar 

  • Patterson KC, Weissmann A, Ahmadi T, Farber HW (2006) Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 145(2):152–153

    PubMed  Google Scholar 

  • Peng F, Yao H, Bai X, Zhu X, Reiner BC, Beazely M, Funa K, Xiong H, Buch S (2010) Platelet-derived growth factor-mediated induction of the synaptic plasticity gene Arc/Arg3.1. J Biol Chem 285(28):21615–21624

    CAS  PubMed Central  PubMed  Google Scholar 

  • Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O et al (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178(1):81–88

    CAS  PubMed  Google Scholar 

  • Pietras K, Sjöblom T, Rubin K, Heldin C-H, Östman A (2003) PDGF receptors as cancer drug targets. Cancer Cell 3:439–443

    CAS  PubMed  Google Scholar 

  • Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck-Radosavljevic M (2012) The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma–a pilot study. Aliment Pharmacol Ther 35(1):83–91

    CAS  PubMed  Google Scholar 

  • Pontén A, Li X, Thorén P, Aase K, Sjöblom T, Östman A, Eriksson U (2003) Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. Am J Pathol 163(2):673–682

    PubMed Central  PubMed  Google Scholar 

  • Pontén A, Folestad EB, Pietras K, Eriksson U (2005) Platelet-derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice. Circ Res 97(10):1036–1045

    PubMed  Google Scholar 

  • Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP, Ghofrani HA et al (2012) Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 32(6):1354–1365

    CAS  PubMed  Google Scholar 

  • Quintas-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R, Cortes J (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25(25):3908–3914

    CAS  PubMed  Google Scholar 

  • Raines EW (2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15(4):237–254

    CAS  PubMed  Google Scholar 

  • Reiberger T, Angermayr B, Schwabl P, Rohr-Udilova N, Mitterhauser M, Gangl A, Peck-Radosavljevic M (2009) Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 51(5):865–873

    CAS  PubMed  Google Scholar 

  • Rhee CK, Lee SH, Yoon HK, Kim SC, Lee SY, Kwon SS, Kim YK, Kim KH, Kim TJ, Kim JW (2011) Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration 82(3):273–287

    CAS  PubMed  Google Scholar 

  • Rice AB, Moomaw CR, Morgan DL, Bonner JC (1999) Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 155(1):213–221

    CAS  PubMed Central  PubMed  Google Scholar 

  • Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365(12):1079–1087

    CAS  PubMed  Google Scholar 

  • Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF (1992) Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339:23–25

    CAS  PubMed  Google Scholar 

  • Rodríguez-González R, Blanco M, Rodríguez-Yáñez M, Moldes O, Castillo J, Sobrino T (2013) Platelet derived growth factor-CC isoform is associated with hemorrhagic transformation in ischemic stroke patients treated with tissue plasminogen activator. Atherosclerosis 226(1):165–171

    PubMed  Google Scholar 

  • Rodt SÅ, Åhlén K, Berg A, Rubin K, Reed RK (1996) A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol 495(Pt 1):193–200

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sano H, Sudo T, Yokode M, Murayama T, Kataoka H, Takakura N, Nishikawa S, Nishikawa SI, Kita T (2001) Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 103(24):2955–2960

    CAS  PubMed  Google Scholar 

  • Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115(10):2811–2821

    CAS  PubMed Central  PubMed  Google Scholar 

  • Schramm C, Schuch G, Lohse AW (2008) Sorafenib-induced liver failure. Am J Gastroenterol 103(8):2162–2163

    PubMed  Google Scholar 

  • Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM (2008) Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 47(5):735–737

    CAS  Google Scholar 

  • Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D et al (2007) An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 357(4):1142–1147

    CAS  PubMed  Google Scholar 

  • Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A et al (2009) Development of a fully human anti-PDGFRβ antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 11(6):594–604

    CAS  PubMed Central  PubMed  Google Scholar 

  • Shiba M, Suzuki H, Fujimoto M, Shimojo N, Imanaka-Yoshida K, Yoshida T, Kanamaru K, Matsushima S, Taki W (2012) Imatinib mesylate prevents cerebral vasospasm after subarachnoid hemorrhage via inhibiting tenascin-C expression in rats. Neurobiol Dis 46(1):172–179

    CAS  PubMed  Google Scholar 

  • Smith CL, Baek ST, Sung CY, Tallquist MD (2011) Epicardial-derived cell epithelial-to-mesenchymal transition and fate specification require PDGF receptor signaling. Circ Res 108(12):e15–e26

    CAS  PubMed Central  PubMed  Google Scholar 

  • Soria A, Cario-Andre M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taieb A (2008) The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 216(2):109–117

    CAS  PubMed  Google Scholar 

  • Soriano P (1994) Abnormal kidney development and hematological disorders in PDGF β-receptor mutant mice. Genes Dev 8(16):1888–1896

    CAS  PubMed  Google Scholar 

  • Soriano P (1997) The PDGFα receptor is required for neural crest cell development and for normal patterning of the somites. Development 124(14):2691–2700

    CAS  PubMed  Google Scholar 

  • Soroceanu L, Akhavan A, Cobbs CS (2008) Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 455(7211):391–395

    CAS  PubMed  Google Scholar 

  • Souza R, Sitbon O, Parent F, Simonneau G, Humbert M (2006) Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61(8):736

    CAS  PubMed Central  PubMed  Google Scholar 

  • Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK (2011) Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 70(6):1003–1009

    CAS  PubMed Central  PubMed  Google Scholar 

  • Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M et al (2008) Activation of PDGF-CC by tissue plasminogen activator impairs blood–brain barrier integrity during ischemic stroke. Nat Med 14(7):731–737

    CAS  PubMed Central  PubMed  Google Scholar 

  • Svegliati Baroni S, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354(25):2667–2676

    Google Scholar 

  • Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, Moroncini G, Bacigalupo A, Leoni P, Avvedimento EV et al (2007) Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110(1):237–241

    CAS  PubMed  Google Scholar 

  • ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S (2009) Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 98(4):265–267

    PubMed  Google Scholar 

  • ten Freyhaus H, Dagnell M, Leuchs M, Vantler M, Berghausen EM, Caglayan E, Weissmann N, Dahal BK, Schermuly RT, Ostman A et al (2011) Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. Am J Respir Crit Care Med 183(8):1092–1102

    PubMed  Google Scholar 

  • ten Freyhaus H, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S (2012) Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs 21(1):119–134

    PubMed  Google Scholar 

  • Thieringer F, Maass T, Czochra P, Klopcic B, Conrad I, Friebe D, Schirmacher P, Lohse AW, Blessing M, Galle PR et al (2008) Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene 423(1):23–28

    CAS  PubMed  Google Scholar 

  • Tuuminen R, Nykanen A, Keranen MA, Krebs R, Alitalo K, Koskinen PK, Lemstrom KB (2006) The effect of platelet-derived growth factor ligands in rat cardiac allograft vasculopathy and fibrosis. Transplant Proc 38(10):3271–3273

    CAS  PubMed  Google Scholar 

  • Ustach CV, Kim HR (2005) Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 25(14):6279–6288

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J, Kim HR (2010) A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res 70(23):9631–9640

    CAS  PubMed Central  PubMed  Google Scholar 

  • van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, van Hagen PM (2008) Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 58(8):2549–2552

    PubMed  Google Scholar 

  • van Roeyen CR, Eitner F, Boor P, Moeller MJ, Raffetseder U, Hanssen L, Bucher E, Villa L, Banas MC, Hudkins KL et al (2011) Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D. Kidney Int 80(12):1292–1305

    PubMed  Google Scholar 

  • Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H (2010) New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 53(1):132–144

    CAS  PubMed  Google Scholar 

  • Wen H, Lu Y, Yao H, Buch S (2011) Morphine induces expression of platelet-derived growth factor in human brain microvascular endothelial cells: implication for vascular permeability. PLoS One 6(6):e21707

    CAS  PubMed Central  PubMed  Google Scholar 

  • Woodruff RH, Fruttiger M, Richardson WD, Franklin RJ (2004) Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci 25(2):252–262

    CAS  PubMed  Google Scholar 

  • Yamasaki Y, Miyoshi K, Oda N, Watanabe M, Miyake H, Chan J, Wang X, Sun L, Tang C, McMahon G et al (2001) Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ Res 88(6):630–636

    CAS  PubMed  Google Scholar 

  • Yao H, Duan M, Buch S (2011) Cocaine-mediated induction of platelet-derived growth factor: implication for increased vascular permeability. Blood 117(8):2538–2547

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zhang ZW, Yanamoto H, Nagata I, Miyamoto S, Nakajo Y, Xue JH, Iihara K, Kikuchi H (2010) Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries: proposed growth factor explanation of cerebral vasospasm. Neurosurgery 66(4):728–735

    PubMed  Google Scholar 

  • Zohlnhöfer D, Hausleiter J, Kastrati A, Mehilli J, Goos C, Schühlen H, Pache J, Pogatsa-Murray G, Heemann U, Dirschinger J et al (2005) A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. J Am Coll Cardiol 46(11):1999–2003

    PubMed  Google Scholar 

Download references

Acknowledgments

Ingegärd Schiller is thanked for her valuable help in the preparation of this article.

Author information

Authors and Affiliations

  1. Ludwig Institute for Cancer Research Ltd, Science for Life Laboratory, Uppsala University, Box 595, SE-75124, Uppsala, Sweden

    Carl-Henrik Heldin

Authors
  1. Carl-Henrik Heldin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carl-Henrik Heldin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heldin, CH. Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases. J Neuroimmune Pharmacol 9, 69–79 (2014). https://doi.org/10.1007/s11481-013-9484-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11481-013-9484-2

Keywords

Search

Navigation